The focus on myeloid leukemia and solid tumors with overexpression of EGFR and/or CD44 was chosen to highlight the differences and similarities of the NDDS design strategies for targeting two seemingly different morphological and molecular types of tumors and to illustrate the impact of novel discoveries in molecular tumor profiles and targeting strategies on the future chemotherapeutic protocols. Here, CD44 is linked to myeloid leukemia.